| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 145 | 2024 | 907 | 13.700 |
Why?
|
| Metalloporphyrins | 33 | 2021 | 103 | 4.480 |
Why?
|
| Pulmonary Emphysema | 33 | 2024 | 267 | 4.240 |
Why?
|
| Smoking | 69 | 2023 | 1382 | 4.070 |
Why?
|
| Superoxide Dismutase | 42 | 2018 | 305 | 3.890 |
Why?
|
| Tomography, X-Ray Computed | 49 | 2024 | 2272 | 2.800 |
Why?
|
| Genetic Predisposition to Disease | 52 | 2023 | 2090 | 2.550 |
Why?
|
| Genome-Wide Association Study | 55 | 2024 | 1176 | 2.480 |
Why?
|
| Lung | 65 | 2024 | 3521 | 2.240 |
Why?
|
| Forced Expiratory Volume | 41 | 2024 | 471 | 2.100 |
Why?
|
| Emphysema | 15 | 2024 | 106 | 2.080 |
Why?
|
| Antioxidants | 26 | 2023 | 529 | 1.990 |
Why?
|
| Genetic Loci | 16 | 2019 | 262 | 1.520 |
Why?
|
| Spirometry | 31 | 2024 | 223 | 1.390 |
Why?
|
| Polymorphism, Single Nucleotide | 38 | 2019 | 1880 | 1.270 |
Why?
|
| Oxidative Stress | 20 | 2016 | 1068 | 1.200 |
Why?
|
| Middle Aged | 123 | 2024 | 26607 | 1.110 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2023 | 70 | 1.100 |
Why?
|
| Reactive Oxygen Species | 17 | 2021 | 522 | 1.100 |
Why?
|
| Smokers | 9 | 2021 | 129 | 1.020 |
Why?
|
| Space Flight | 2 | 2023 | 127 | 0.990 |
Why?
|
| Aged | 99 | 2023 | 18971 | 0.980 |
Why?
|
| Male | 151 | 2024 | 55400 | 0.970 |
Why?
|
| Humans | 212 | 2024 | 114050 | 0.950 |
Why?
|
| Female | 141 | 2024 | 59328 | 0.910 |
Why?
|
| Pneumonia | 6 | 2021 | 563 | 0.900 |
Why?
|
| Vital Capacity | 19 | 2024 | 254 | 0.880 |
Why?
|
| Severity of Illness Index | 34 | 2022 | 2537 | 0.840 |
Why?
|
| Retina | 2 | 2023 | 263 | 0.800 |
Why?
|
| Bronchitis, Chronic | 7 | 2019 | 17 | 0.790 |
Why?
|
| Respiratory Function Tests | 21 | 2020 | 522 | 0.780 |
Why?
|
| Disease Progression | 22 | 2023 | 2371 | 0.740 |
Why?
|
| Radiation-Protective Agents | 8 | 2017 | 26 | 0.720 |
Why?
|
| Extracellular Space | 12 | 2011 | 116 | 0.710 |
Why?
|
| Free Radical Scavengers | 6 | 2010 | 78 | 0.680 |
Why?
|
| Addison Disease | 1 | 2019 | 40 | 0.660 |
Why?
|
| Phenotype | 22 | 2023 | 2784 | 0.650 |
Why?
|
| Premature Birth | 2 | 2021 | 275 | 0.650 |
Why?
|
| Clinical Protocols | 1 | 2019 | 232 | 0.610 |
Why?
|
| Pulmonary Artery | 7 | 2021 | 1024 | 0.590 |
Why?
|
| Aged, 80 and over | 38 | 2022 | 6307 | 0.590 |
Why?
|
| Mice | 42 | 2023 | 14845 | 0.580 |
Why?
|
| Risk Factors | 38 | 2023 | 8614 | 0.560 |
Why?
|
| Lung Diseases | 6 | 2015 | 690 | 0.560 |
Why?
|
| Biomarkers | 14 | 2023 | 3397 | 0.560 |
Why?
|
| Animals | 64 | 2023 | 31567 | 0.530 |
Why?
|
| Asthma | 12 | 2019 | 2021 | 0.510 |
Why?
|
| Quality of Life | 17 | 2023 | 2343 | 0.510 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 2384 | 0.490 |
Why?
|
| Comorbidity | 12 | 2022 | 1447 | 0.480 |
Why?
|
| Case-Control Studies | 21 | 2020 | 3003 | 0.460 |
Why?
|
| Respiratory System | 5 | 2016 | 137 | 0.450 |
Why?
|
| Respiratory Tract Diseases | 3 | 2020 | 139 | 0.450 |
Why?
|
| Prospective Studies | 17 | 2024 | 6195 | 0.450 |
Why?
|
| Vascular Diseases | 2 | 2021 | 233 | 0.440 |
Why?
|
| Pulmonary Fibrosis | 5 | 2019 | 321 | 0.430 |
Why?
|
| Genetic Markers | 6 | 2019 | 320 | 0.420 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 5 | 2019 | 500 | 0.410 |
Why?
|
| Cohort Studies | 22 | 2023 | 4883 | 0.400 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2003 | 94 | 0.400 |
Why?
|
| Pulmonary Alveoli | 7 | 2017 | 372 | 0.390 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 4402 | 0.380 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 282 | 0.370 |
Why?
|
| Receptors, Nicotinic | 5 | 2019 | 273 | 0.350 |
Why?
|
| Guinea Pigs | 3 | 2019 | 136 | 0.340 |
Why?
|
| Macrophages | 5 | 2011 | 1259 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 17 | 2023 | 4681 | 0.330 |
Why?
|
| Bronchopulmonary Dysplasia | 4 | 2011 | 333 | 0.330 |
Why?
|
| Transforming Growth Factor beta2 | 2 | 2019 | 31 | 0.320 |
Why?
|
| Mycobacterium | 1 | 2010 | 103 | 0.320 |
Why?
|
| GTPase-Activating Proteins | 6 | 2019 | 72 | 0.320 |
Why?
|
| Rabbits | 5 | 2019 | 733 | 0.320 |
Why?
|
| Gene Expression | 8 | 2019 | 1417 | 0.310 |
Why?
|
| Disease Models, Animal | 16 | 2016 | 3498 | 0.310 |
Why?
|
| Genetic Variation | 6 | 2019 | 868 | 0.310 |
Why?
|
| United States | 26 | 2019 | 12137 | 0.310 |
Why?
|
| Reactive Nitrogen Species | 3 | 2016 | 21 | 0.300 |
Why?
|
| Quantitative Trait Loci | 8 | 2019 | 304 | 0.290 |
Why?
|
| Oxidation-Reduction | 9 | 2018 | 917 | 0.290 |
Why?
|
| Cartilage, Articular | 2 | 2015 | 286 | 0.290 |
Why?
|
| Adult | 26 | 2021 | 30377 | 0.280 |
Why?
|
| Catalysis | 4 | 2011 | 289 | 0.280 |
Why?
|
| Haplotypes | 1 | 2008 | 448 | 0.280 |
Why?
|
| Models, Statistical | 3 | 2020 | 595 | 0.280 |
Why?
|
| Maze Learning | 3 | 2006 | 87 | 0.270 |
Why?
|
| Machine Learning | 2 | 2020 | 315 | 0.270 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2008 | 200 | 0.270 |
Why?
|
| Finland | 2 | 2021 | 69 | 0.260 |
Why?
|
| Bleomycin | 3 | 2012 | 228 | 0.260 |
Why?
|
| Memory Disorders | 2 | 2017 | 153 | 0.260 |
Why?
|
| Oxygen | 5 | 2018 | 851 | 0.260 |
Why?
|
| Total Lung Capacity | 4 | 2020 | 30 | 0.260 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2010 | 270 | 0.260 |
Why?
|
| Sepharose | 2 | 2006 | 31 | 0.250 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2018 | 52 | 0.250 |
Why?
|
| Acute Lung Injury | 1 | 2008 | 268 | 0.250 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1875 | 0.250 |
Why?
|
| Airway Remodeling | 4 | 2018 | 57 | 0.250 |
Why?
|
| Cluster Analysis | 5 | 2019 | 452 | 0.250 |
Why?
|
| Osteoarthritis, Hip | 1 | 2005 | 38 | 0.240 |
Why?
|
| Heparin | 3 | 2005 | 225 | 0.240 |
Why?
|
| Exome | 2 | 2016 | 200 | 0.240 |
Why?
|
| Transcriptome | 3 | 2023 | 723 | 0.240 |
Why?
|
| Polymorphism, Genetic | 5 | 2015 | 610 | 0.240 |
Why?
|
| Tissue Fixation | 1 | 2004 | 27 | 0.240 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 4392 | 0.240 |
Why?
|
| Organ Preservation Solutions | 1 | 2004 | 37 | 0.230 |
Why?
|
| Sleep Wake Disorders | 2 | 2020 | 232 | 0.230 |
Why?
|
| Organ Preservation | 1 | 2004 | 64 | 0.230 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2015 | 93 | 0.230 |
Why?
|
| Periodicals as Topic | 3 | 2020 | 180 | 0.230 |
Why?
|
| Mucus | 2 | 2014 | 54 | 0.230 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2018 | 160 | 0.230 |
Why?
|
| Carrier Proteins | 4 | 2017 | 694 | 0.220 |
Why?
|
| Aging | 2 | 2005 | 1612 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2015 | 24 | 0.220 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 1791 | 0.220 |
Why?
|
| Interleukin-18 | 2 | 2011 | 217 | 0.220 |
Why?
|
| Thioredoxins | 1 | 2003 | 33 | 0.220 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2017 | 102 | 0.220 |
Why?
|
| Interleukin-2 | 2 | 2009 | 413 | 0.220 |
Why?
|
| Photoreceptor Cells | 1 | 2023 | 12 | 0.210 |
Why?
|
| Logistic Models | 9 | 2020 | 1829 | 0.210 |
Why?
|
| Skin | 3 | 2016 | 653 | 0.210 |
Why?
|
| Extracellular Matrix | 5 | 2010 | 436 | 0.210 |
Why?
|
| DNA Methylation | 3 | 2019 | 493 | 0.210 |
Why?
|
| Bronchodilator Agents | 4 | 2016 | 239 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2013 | 1837 | 0.210 |
Why?
|
| Apoptosis | 5 | 2018 | 2349 | 0.210 |
Why?
|
| Rats | 14 | 2013 | 4913 | 0.210 |
Why?
|
| Inflammation | 8 | 2019 | 2464 | 0.210 |
Why?
|
| Prostatic Neoplasms | 4 | 2012 | 913 | 0.210 |
Why?
|
| Genotype | 8 | 2018 | 1757 | 0.210 |
Why?
|
| Molecular Epidemiology | 2 | 2019 | 62 | 0.210 |
Why?
|
| Golgi Apparatus | 2 | 2004 | 89 | 0.210 |
Why?
|
| Nitric Oxide Synthase | 4 | 2009 | 209 | 0.200 |
Why?
|
| Tobacco Products | 1 | 2023 | 98 | 0.200 |
Why?
|
| Subtilisins | 1 | 2002 | 9 | 0.200 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2002 | 60 | 0.200 |
Why?
|
| Carotid Arteries | 2 | 2021 | 180 | 0.200 |
Why?
|
| Risk Assessment | 7 | 2020 | 2958 | 0.190 |
Why?
|
| Papio | 7 | 2011 | 96 | 0.190 |
Why?
|
| Administration, Cutaneous | 2 | 2019 | 117 | 0.190 |
Why?
|
| Exercise Tolerance | 5 | 2015 | 212 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 4 | 2015 | 527 | 0.190 |
Why?
|
| Neoplasms | 2 | 2006 | 2086 | 0.190 |
Why?
|
| Airway Obstruction | 1 | 2024 | 160 | 0.190 |
Why?
|
| Linear Models | 7 | 2018 | 768 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2003 | 495 | 0.190 |
Why?
|
| Toxicity Tests | 2 | 2019 | 28 | 0.190 |
Why?
|
| Sputum | 3 | 2013 | 286 | 0.190 |
Why?
|
| Linkage Disequilibrium | 5 | 2017 | 245 | 0.190 |
Why?
|
| Belgium | 1 | 2021 | 11 | 0.190 |
Why?
|
| Republic of Korea | 1 | 2021 | 27 | 0.190 |
Why?
|
| Poland | 1 | 2021 | 29 | 0.190 |
Why?
|
| Spain | 1 | 2021 | 32 | 0.180 |
Why?
|
| Genetic Association Studies | 4 | 2018 | 339 | 0.180 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 2322 | 0.180 |
Why?
|
| Forecasting | 2 | 2022 | 331 | 0.180 |
Why?
|
| Chemokines | 2 | 2017 | 215 | 0.180 |
Why?
|
| Sweden | 1 | 2021 | 65 | 0.180 |
Why?
|
| Japan | 1 | 2021 | 85 | 0.180 |
Why?
|
| Intraocular Pressure | 1 | 2023 | 275 | 0.180 |
Why?
|
| Germany | 1 | 2021 | 84 | 0.180 |
Why?
|
| Iron Regulatory Protein 2 | 3 | 2015 | 6 | 0.180 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 100 | 0.180 |
Why?
|
| Data Collection | 2 | 2015 | 618 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 90 | 0.180 |
Why?
|
| Cytokines | 4 | 2017 | 1824 | 0.170 |
Why?
|
| Nitric Oxide | 4 | 2008 | 817 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2013 | 159 | 0.170 |
Why?
|
| Desmoplakins | 2 | 2019 | 19 | 0.170 |
Why?
|
| Blood Vessels | 2 | 2013 | 179 | 0.170 |
Why?
|
| Mice, Transgenic | 7 | 2015 | 1947 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 175 | 0.170 |
Why?
|
| Swine | 3 | 2019 | 687 | 0.170 |
Why?
|
| Canada | 1 | 2021 | 320 | 0.170 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 57 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2013 | 2182 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2003 | 372 | 0.170 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2019 | 153 | 0.170 |
Why?
|
| Biomimetic Materials | 2 | 2018 | 64 | 0.170 |
Why?
|
| Gene Expression Profiling | 7 | 2023 | 1518 | 0.170 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 31 | 0.170 |
Why?
|
| Hypoxia | 3 | 2016 | 956 | 0.170 |
Why?
|
| Lymphoma | 2 | 2012 | 176 | 0.170 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2019 | 4 | 0.160 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Prevalence | 6 | 2023 | 2247 | 0.160 |
Why?
|
| Activin Receptors, Type I | 1 | 2019 | 9 | 0.160 |
Why?
|
| Infant, Newborn | 6 | 2021 | 5038 | 0.160 |
Why?
|
| Swine, Miniature | 1 | 2019 | 70 | 0.160 |
Why?
|
| Global Health | 1 | 2021 | 287 | 0.160 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 21 | 0.160 |
Why?
|
| Genome, Human | 4 | 2019 | 347 | 0.160 |
Why?
|
| Surveys and Questionnaires | 11 | 2022 | 4595 | 0.160 |
Why?
|
| Critical Care | 2 | 2020 | 472 | 0.160 |
Why?
|
| Macaca fascicularis | 2 | 2016 | 50 | 0.160 |
Why?
|
| Blood Flow Velocity | 2 | 2017 | 388 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2003 | 600 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 150 | 0.160 |
Why?
|
| Psoriasis | 1 | 2019 | 80 | 0.150 |
Why?
|
| Blood Pressure | 3 | 2009 | 1531 | 0.150 |
Why?
|
| Dexamethasone | 2 | 2012 | 316 | 0.150 |
Why?
|
| Ventricular Function, Right | 2 | 2017 | 256 | 0.150 |
Why?
|
| Causality | 1 | 2019 | 104 | 0.150 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 153 | 0.150 |
Why?
|
| Pectoralis Muscles | 1 | 2018 | 13 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 94 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 118 | 0.150 |
Why?
|
| Epidemiologic Studies | 2 | 2015 | 57 | 0.150 |
Why?
|
| Phagocytosis | 2 | 2011 | 349 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2019 | 151 | 0.150 |
Why?
|
| Down-Regulation | 4 | 2010 | 594 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2015 | 28 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 195 | 0.150 |
Why?
|
| Hydrocortisone | 1 | 2019 | 267 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 224 | 0.150 |
Why?
|
| Acetylcysteine | 2 | 2010 | 141 | 0.150 |
Why?
|
| Aorta | 6 | 2012 | 388 | 0.140 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2017 | 64 | 0.140 |
Why?
|
| Enzyme Activation | 5 | 2012 | 771 | 0.140 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 229 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 4 | 2018 | 1144 | 0.140 |
Why?
|
| Heart | 2 | 2015 | 613 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1422 | 0.140 |
Why?
|
| Monocytes | 2 | 2011 | 503 | 0.140 |
Why?
|
| Databases, Genetic | 1 | 2018 | 206 | 0.140 |
Why?
|
| Proteins | 3 | 2010 | 906 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 926 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2019 | 526 | 0.140 |
Why?
|
| Hemizygote | 1 | 2016 | 3 | 0.140 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 1624 | 0.140 |
Why?
|
| Catalase | 4 | 2010 | 118 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 49 | 0.140 |
Why?
|
| Health Status | 4 | 2014 | 716 | 0.140 |
Why?
|
| Time Factors | 10 | 2020 | 6077 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 295 | 0.130 |
Why?
|
| Attention | 1 | 2019 | 394 | 0.130 |
Why?
|
| Interleukin-27 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 381 | 0.130 |
Why?
|
| Cognition | 2 | 2021 | 990 | 0.130 |
Why?
|
| Pruritus | 1 | 2016 | 59 | 0.130 |
Why?
|
| Free Radicals | 2 | 2009 | 99 | 0.130 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 9 | 0.130 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2019 | 41 | 0.130 |
Why?
|
| Uteroglobin | 2 | 2013 | 16 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 684 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 2087 | 0.130 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 57 | 0.130 |
Why?
|
| Respiratory Mechanics | 2 | 2013 | 56 | 0.130 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2013 | 28 | 0.130 |
Why?
|
| Cell Line | 5 | 2016 | 2629 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2017 | 128 | 0.130 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 97 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 571 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 221 | 0.130 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2011 | 580 | 0.130 |
Why?
|
| Endothelins | 1 | 2016 | 61 | 0.130 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 307 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 183 | 0.130 |
Why?
|
| Disease Management | 1 | 2019 | 556 | 0.130 |
Why?
|
| Dyspnea | 4 | 2024 | 212 | 0.130 |
Why?
|
| Cadherins | 1 | 2017 | 175 | 0.130 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2016 | 63 | 0.130 |
Why?
|
| Cells, Cultured | 6 | 2018 | 3861 | 0.130 |
Why?
|
| Heart Rate | 2 | 2016 | 710 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 94 | 0.120 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 410 | 0.120 |
Why?
|
| Eye | 1 | 2016 | 97 | 0.120 |
Why?
|
| Galactosylceramidase | 1 | 2015 | 3 | 0.120 |
Why?
|
| Prognosis | 5 | 2020 | 3315 | 0.120 |
Why?
|
| Research Design | 2 | 2019 | 919 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 79 | 0.120 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 24 | 0.120 |
Why?
|
| Brain | 3 | 2023 | 2355 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 27 | 0.120 |
Why?
|
| Computational Biology | 2 | 2016 | 528 | 0.120 |
Why?
|
| Islets of Langerhans | 2 | 2018 | 728 | 0.120 |
Why?
|
| Tyrosine | 2 | 2005 | 210 | 0.120 |
Why?
|
| Fibroblasts | 1 | 2019 | 834 | 0.120 |
Why?
|
| Occupational Exposure | 2 | 2014 | 255 | 0.120 |
Why?
|
| Axonemal Dyneins | 1 | 2014 | 8 | 0.120 |
Why?
|
| Molecular Mimicry | 3 | 2003 | 35 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 55 | 0.120 |
Why?
|
| Chemokines, CC | 1 | 2014 | 28 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2016 | 222 | 0.120 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2011 | 217 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 286 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2006 | 95 | 0.110 |
Why?
|
| Spinal Fractures | 1 | 2015 | 74 | 0.110 |
Why?
|
| Bronchitis | 2 | 2015 | 35 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 388 | 0.110 |
Why?
|
| Psychometrics | 1 | 2017 | 608 | 0.110 |
Why?
|
| Proctitis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 155 | 0.110 |
Why?
|
| Hypertension | 2 | 2019 | 1052 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 122 | 0.110 |
Why?
|
| Alleles | 4 | 2017 | 789 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 756 | 0.110 |
Why?
|
| Radiography, Thoracic | 4 | 2015 | 150 | 0.110 |
Why?
|
| Chromosome Mapping | 4 | 2015 | 486 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 2764 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 286 | 0.110 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2013 | 46 | 0.110 |
Why?
|
| Pamphlets | 1 | 2013 | 22 | 0.110 |
Why?
|
| Kidney | 3 | 2016 | 1182 | 0.110 |
Why?
|
| Liver | 3 | 2016 | 1633 | 0.110 |
Why?
|
| Dendritic Cells | 3 | 2016 | 435 | 0.100 |
Why?
|
| Glutathione Peroxidase | 2 | 2010 | 40 | 0.100 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2013 | 43 | 0.100 |
Why?
|
| Graft Survival | 2 | 2018 | 443 | 0.100 |
Why?
|
| Body Mass Index | 4 | 2017 | 1957 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 427 | 0.100 |
Why?
|
| Physical Conditioning, Animal | 1 | 2015 | 194 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 255 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2018 | 945 | 0.100 |
Why?
|
| Glycine | 2 | 2005 | 152 | 0.100 |
Why?
|
| Receptors, Serotonin, 5-HT4 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Heart Ventricles | 1 | 2017 | 723 | 0.100 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 239 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 2700 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2014 | 193 | 0.100 |
Why?
|
| Rectum | 1 | 2013 | 151 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2012 | 22 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2014 | 172 | 0.100 |
Why?
|
| Telecommunications | 1 | 2012 | 16 | 0.100 |
Why?
|
| Elastin | 3 | 2010 | 78 | 0.100 |
Why?
|
| Arginine | 2 | 2005 | 236 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2015 | 224 | 0.100 |
Why?
|
| Registries | 1 | 2019 | 1764 | 0.100 |
Why?
|
| Multigene Family | 1 | 2013 | 190 | 0.100 |
Why?
|
| Protons | 1 | 2012 | 73 | 0.100 |
Why?
|
| Thymus Neoplasms | 1 | 2012 | 20 | 0.100 |
Why?
|
| Computers | 2 | 2022 | 60 | 0.100 |
Why?
|
| Interleukin-8 | 2 | 2012 | 229 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Neutrophils | 4 | 2010 | 1089 | 0.100 |
Why?
|
| Biomedical Research | 2 | 2011 | 582 | 0.100 |
Why?
|
| Animals, Newborn | 4 | 2009 | 777 | 0.100 |
Why?
|
| Research | 1 | 2015 | 389 | 0.100 |
Why?
|
| Walking | 2 | 2015 | 422 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 229 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2012 | 175 | 0.090 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2011 | 12 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2015 | 329 | 0.090 |
Why?
|
| Bone Density | 1 | 2015 | 432 | 0.090 |
Why?
|
| Protein Folding | 3 | 2008 | 239 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2014 | 1578 | 0.090 |
Why?
|
| RNA, Messenger | 6 | 2014 | 2550 | 0.090 |
Why?
|
| NF-kappa B | 3 | 2011 | 636 | 0.090 |
Why?
|
| Leukocyte Elastase | 1 | 2011 | 71 | 0.090 |
Why?
|
| Collagen | 2 | 2005 | 414 | 0.090 |
Why?
|
| Superoxides | 2 | 2008 | 190 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2018 | 1206 | 0.090 |
Why?
|
| Radiography | 4 | 2015 | 803 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2015 | 53 | 0.090 |
Why?
|
| Mycobacterium avium Complex | 1 | 2011 | 89 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 1128 | 0.090 |
Why?
|
| Aconitate Hydratase | 3 | 2009 | 16 | 0.090 |
Why?
|
| Microbial Viability | 1 | 2011 | 79 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2011 | 63 | 0.090 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Inflammasomes | 1 | 2012 | 115 | 0.090 |
Why?
|
| Radiology | 1 | 2012 | 137 | 0.090 |
Why?
|
| International Cooperation | 1 | 2011 | 169 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 695 | 0.090 |
Why?
|
| Depression | 1 | 2018 | 1133 | 0.090 |
Why?
|
| Child | 5 | 2021 | 18404 | 0.090 |
Why?
|
| Pregnancy | 1 | 2021 | 5499 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2010 | 24 | 0.080 |
Why?
|
| Mycobacterium Infections | 1 | 2010 | 61 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 68 | 0.080 |
Why?
|
| Interleukins | 1 | 2011 | 236 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 127 | 0.080 |
Why?
|
| Rest | 3 | 2016 | 103 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 1736 | 0.080 |
Why?
|
| Endocytosis | 1 | 2010 | 146 | 0.080 |
Why?
|
| Porphyrins | 1 | 2009 | 16 | 0.080 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2009 | 35 | 0.080 |
Why?
|
| Organ Size | 4 | 2016 | 434 | 0.080 |
Why?
|
| Proof of Concept Study | 2 | 2019 | 47 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2016 | 476 | 0.080 |
Why?
|
| Molecular Sequence Data | 5 | 2008 | 2783 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 225 | 0.080 |
Why?
|
| Hospitalization | 2 | 2014 | 1762 | 0.080 |
Why?
|
| Phagosomes | 1 | 2008 | 38 | 0.080 |
Why?
|
| Environment | 1 | 2010 | 333 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 102 | 0.080 |
Why?
|
| Macrophages, Alveolar | 1 | 2011 | 348 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2009 | 802 | 0.080 |
Why?
|
| Oxidants | 2 | 2011 | 112 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 234 | 0.080 |
Why?
|
| Smoking Prevention | 1 | 2009 | 157 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2016 | 951 | 0.080 |
Why?
|
| Lysosomes | 1 | 2008 | 123 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2017 | 9049 | 0.070 |
Why?
|
| RNA | 3 | 2019 | 806 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1381 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2005 | 157 | 0.070 |
Why?
|
| Incidence | 4 | 2015 | 2314 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 373 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 2886 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2011 | 946 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2011 | 2563 | 0.070 |
Why?
|
| Walk Test | 2 | 2018 | 52 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 300 | 0.070 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 2007 | 6 | 0.070 |
Why?
|
| Bombesin | 1 | 2007 | 12 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2003 | 499 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2011 | 723 | 0.070 |
Why?
|
| T-Lymphocytes | 3 | 2007 | 1735 | 0.070 |
Why?
|
| Europe | 2 | 2019 | 332 | 0.070 |
Why?
|
| Exercise Test | 3 | 2015 | 547 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 362 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 1471 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1078 | 0.070 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 1981 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 744 | 0.070 |
Why?
|
| Journalism, Medical | 1 | 2006 | 5 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2005 | 4501 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 898 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 200 | 0.070 |
Why?
|
| Smoke | 2 | 2010 | 123 | 0.070 |
Why?
|
| Models, Biological | 3 | 2016 | 1611 | 0.070 |
Why?
|
| Mutation | 4 | 2018 | 3338 | 0.070 |
Why?
|
| Body Weight | 5 | 2010 | 868 | 0.070 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2006 | 40 | 0.070 |
Why?
|
| Propensity Score | 2 | 2019 | 225 | 0.070 |
Why?
|
| Estrogens | 1 | 2009 | 312 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 796 | 0.060 |
Why?
|
| Tobacco Industry | 1 | 2006 | 46 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 2 | 2019 | 9 | 0.060 |
Why?
|
| Mice, Inbred CBA | 1 | 2005 | 49 | 0.060 |
Why?
|
| Proteomics | 2 | 2023 | 815 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 68 | 0.060 |
Why?
|
| Lipid Peroxidation | 2 | 2003 | 139 | 0.060 |
Why?
|
| Estradiol | 1 | 2009 | 450 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 77 | 0.060 |
Why?
|
| Mothers | 1 | 2011 | 650 | 0.060 |
Why?
|
| Head Injuries, Closed | 1 | 2006 | 49 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2014 | 1218 | 0.060 |
Why?
|
| Femur Head | 1 | 2005 | 31 | 0.060 |
Why?
|
| Nitrates | 1 | 2005 | 71 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 2006 | 743 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 280 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2005 | 52 | 0.060 |
Why?
|
| Oximetry | 2 | 2016 | 79 | 0.060 |
Why?
|
| Dimerization | 4 | 2007 | 176 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 315 | 0.060 |
Why?
|
| Hindlimb | 1 | 2005 | 130 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2002 | 147 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2022 | 12521 | 0.060 |
Why?
|
| Cell Division | 2 | 2004 | 754 | 0.060 |
Why?
|
| Glutaral | 1 | 2004 | 14 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2004 | 46 | 0.060 |
Why?
|
| CpG Islands | 2 | 2015 | 118 | 0.060 |
Why?
|
| Intercellular Junctions | 1 | 2004 | 33 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 1350 | 0.060 |
Why?
|
| NADPH Oxidases | 1 | 2005 | 105 | 0.060 |
Why?
|
| Executive Function | 2 | 2020 | 380 | 0.060 |
Why?
|
| Protein Binding | 3 | 2010 | 1888 | 0.060 |
Why?
|
| Immunochemistry | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cough | 2 | 2016 | 107 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 2 | 2014 | 23 | 0.060 |
Why?
|
| Injections | 1 | 2004 | 160 | 0.060 |
Why?
|
| Tibia | 1 | 2005 | 166 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 316 | 0.060 |
Why?
|
| Heart Failure | 1 | 2016 | 1958 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2017 | 513 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 130 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 722 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2004 | 158 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 924 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2004 | 108 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 80 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2005 | 1143 | 0.050 |
Why?
|
| Triglycerides | 1 | 2005 | 467 | 0.050 |
Why?
|
| Biomimetics | 1 | 2003 | 36 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2003 | 128 | 0.050 |
Why?
|
| Myocardium | 2 | 2005 | 911 | 0.050 |
Why?
|
| X Chromosome | 1 | 2023 | 47 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1726 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2004 | 217 | 0.050 |
Why?
|
| Norway | 2 | 2014 | 36 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2013 | 3254 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2005 | 251 | 0.050 |
Why?
|
| Genotyping Techniques | 2 | 2014 | 69 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 60 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 35 | 0.050 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2002 | 23 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2004 | 622 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2023 | 177 | 0.050 |
Why?
|
| Brefeldin A | 1 | 2002 | 14 | 0.050 |
Why?
|
| Fibrinogen | 2 | 2013 | 143 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2002 | 161 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2014 | 336 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 88 | 0.050 |
Why?
|
| Furin | 1 | 2002 | 12 | 0.050 |
Why?
|
| Endotoxemia | 1 | 2003 | 86 | 0.050 |
Why?
|
| Hemodynamics | 2 | 2004 | 1015 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 429 | 0.050 |
Why?
|
| Seizures | 1 | 2005 | 337 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 42 | 0.050 |
Why?
|
| CHO Cells | 1 | 2002 | 137 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 307 | 0.050 |
Why?
|
| Dogs | 1 | 2002 | 331 | 0.050 |
Why?
|
| Hyperoxia | 1 | 2003 | 99 | 0.050 |
Why?
|
| Cricetinae | 1 | 2002 | 252 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 256 | 0.050 |
Why?
|
| Age of Onset | 2 | 2014 | 444 | 0.050 |
Why?
|
| Smoking Cessation | 2 | 2018 | 374 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 110 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 285 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2012 | 315 | 0.050 |
Why?
|
| Disulfides | 3 | 2008 | 90 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 29 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2002 | 121 | 0.050 |
Why?
|
| Genomics | 2 | 2018 | 631 | 0.050 |
Why?
|
| Polymers | 1 | 2004 | 448 | 0.050 |
Why?
|
| Acute Disease | 2 | 2014 | 908 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 347 | 0.040 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 362 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2002 | 327 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2003 | 252 | 0.040 |
Why?
|
| DNA Damage | 2 | 2013 | 351 | 0.040 |
Why?
|
| Hippocampus | 1 | 2005 | 690 | 0.040 |
Why?
|
| Eosinophils | 1 | 2002 | 276 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 249 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 845 | 0.040 |
Why?
|
| Air | 1 | 2020 | 32 | 0.040 |
Why?
|
| Lung Compliance | 2 | 2010 | 47 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 183 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 298 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 166 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 24 | 0.040 |
Why?
|
| rab4 GTP-Binding Proteins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Temperature | 1 | 2002 | 564 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 42 | 0.040 |
Why?
|
| Hydrogen Peroxide | 2 | 2012 | 288 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 178 | 0.040 |
Why?
|
| Colorado | 1 | 2008 | 4090 | 0.040 |
Why?
|
| Sleep Medicine Specialty | 1 | 2019 | 9 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 128 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 40 | 0.040 |
Why?
|
| Epigenomics | 1 | 2019 | 98 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 268 | 0.040 |
Why?
|
| Biofilms | 1 | 2021 | 223 | 0.040 |
Why?
|
| Fetus | 1 | 2003 | 698 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 122 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 348 | 0.040 |
Why?
|
| Education | 2 | 2012 | 93 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 830 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2019 | 69 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 88 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 133 | 0.040 |
Why?
|
| Systems Biology | 1 | 2018 | 54 | 0.040 |
Why?
|
| Adiponectin | 1 | 2019 | 213 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 257 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 373 | 0.040 |
Why?
|
| Mucin-5B | 1 | 2019 | 184 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 278 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 204 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2017 | 60 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 385 | 0.040 |
Why?
|
| Lipopolysaccharides | 3 | 2008 | 813 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 241 | 0.030 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 2016 | 4 | 0.030 |
Why?
|
| Skin Cream | 1 | 2016 | 7 | 0.030 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 2016 | 2 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 195 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 383 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 398 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 336 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 172 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2016 | 13 | 0.030 |
Why?
|
| Ear | 1 | 2016 | 31 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 274 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 29 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 17802 | 0.030 |
Why?
|
| Culture | 1 | 2017 | 122 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2003 | 637 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 437 | 0.030 |
Why?
|
| Spleen | 2 | 2009 | 485 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 44 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 932 | 0.030 |
Why?
|
| Boston | 1 | 2016 | 76 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 283 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 258 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2016 | 166 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 828 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1117 | 0.030 |
Why?
|
| Cytokinesis | 1 | 2016 | 46 | 0.030 |
Why?
|
| Reaction Time | 1 | 2017 | 373 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 204 | 0.030 |
Why?
|
| Myocardial Reperfusion | 2 | 2006 | 50 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2008 | 261 | 0.030 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2015 | 29 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2016 | 241 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 271 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 114 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 2 | 2005 | 43 | 0.030 |
Why?
|
| Health Planning Councils | 1 | 2015 | 6 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 137 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2016 | 215 | 0.030 |
Why?
|
| Shock | 1 | 2016 | 83 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 343 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 156 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 95 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 16 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2016 | 177 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 511 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 2 | 2006 | 115 | 0.030 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2014 | 29 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 799 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 57 | 0.030 |
Why?
|
| Chromatography, Affinity | 2 | 2005 | 80 | 0.030 |
Why?
|
| Base Sequence | 2 | 2008 | 2114 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 725 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 465 | 0.030 |
Why?
|
| alpha-Mannosidase | 1 | 2014 | 2 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 368 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 511 | 0.030 |
Why?
|
| Mannosidases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 926 | 0.030 |
Why?
|
| Thiolester Hydrolases | 1 | 2014 | 9 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2011 | 719 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 273 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 20 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 545 | 0.030 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 810 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2014 | 294 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 151 | 0.030 |
Why?
|
| Desmosine | 1 | 2013 | 6 | 0.030 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2013 | 5 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 134 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2013 | 60 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 90 | 0.030 |
Why?
|
| Foundations | 1 | 2013 | 22 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 873 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 283 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 2 | 2003 | 20 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 39 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 223 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 899 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 52 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 445 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 518 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 134 | 0.030 |
Why?
|
| Health Services | 1 | 2013 | 103 | 0.030 |
Why?
|
| Morbidity | 1 | 2013 | 277 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 122 | 0.030 |
Why?
|
| Angiography | 1 | 2013 | 176 | 0.030 |
Why?
|
| Osteoarthritis | 1 | 2015 | 169 | 0.030 |
Why?
|
| Running | 1 | 2015 | 207 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 50 | 0.030 |
Why?
|
| Penis | 1 | 2012 | 37 | 0.030 |
Why?
|
| Homeostasis | 1 | 2016 | 570 | 0.030 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 38 | 0.030 |
Why?
|
| Aortography | 1 | 2012 | 50 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2012 | 71 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2012 | 60 | 0.020 |
Why?
|
| Hemolysis | 1 | 2013 | 143 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 477 | 0.020 |
Why?
|
| Automation | 1 | 2012 | 74 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2015 | 277 | 0.020 |
Why?
|
| Testis | 1 | 2012 | 133 | 0.020 |
Why?
|
| Bronchospirometry | 1 | 2011 | 1 | 0.020 |
Why?
|
| Knee Joint | 1 | 2015 | 322 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1469 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2013 | 126 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 291 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 234 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2013 | 230 | 0.020 |
Why?
|
| Telephone | 1 | 2012 | 152 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1310 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 140 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 298 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 110 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2011 | 68 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 590 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1024 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 2159 | 0.020 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2010 | 22 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 144 | 0.020 |
Why?
|
| Pancreatic Elastase | 1 | 2010 | 55 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 39 | 0.020 |
Why?
|
| Glutathione | 1 | 2012 | 293 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 59 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 102 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 169 | 0.020 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2010 | 21 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 175 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 127 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 282 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 29 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 180 | 0.020 |
Why?
|
| Plasma | 1 | 2011 | 181 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 492 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 925 | 0.020 |
Why?
|
| Receptors, Estradiol | 1 | 2009 | 3 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 92 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 106 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 34 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2010 | 133 | 0.020 |
Why?
|
| Neuroglia | 1 | 2010 | 149 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 787 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1707 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 673 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 377 | 0.020 |
Why?
|
| Ductus Arteriosus | 1 | 2009 | 67 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 761 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1690 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 7944 | 0.020 |
Why?
|
| Denmark | 1 | 2008 | 39 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 79 | 0.020 |
Why?
|
| Insulin | 1 | 2018 | 2080 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2009 | 368 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2008 | 193 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 186 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2009 | 99 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 328 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 591 | 0.020 |
Why?
|
| Leukocytes | 1 | 2009 | 272 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 714 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 508 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 760 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 863 | 0.020 |
Why?
|
| Body Composition | 1 | 2010 | 590 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 292 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2006 | 16 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 496 | 0.020 |
Why?
|
| Family | 1 | 2010 | 589 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 326 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 386 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 51 | 0.020 |
Why?
|
| Peroxisomes | 1 | 2005 | 9 | 0.020 |
Why?
|
| Protein Carbonylation | 1 | 2006 | 51 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 250 | 0.020 |
Why?
|
| Manganese | 1 | 2006 | 55 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 79 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 198 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 221 | 0.020 |
Why?
|
| Chromatography, Agarose | 1 | 2005 | 4 | 0.020 |
Why?
|
| Microvilli | 1 | 2005 | 70 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 528 | 0.020 |
Why?
|
| Brain Injuries | 1 | 2010 | 459 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 341 | 0.010 |
Why?
|
| Caveolins | 1 | 2004 | 5 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 174 | 0.010 |
Why?
|
| Caveolae | 1 | 2004 | 15 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 2005 | 135 | 0.010 |
Why?
|
| Trypsin | 1 | 2004 | 66 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 380 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 408 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 391 | 0.010 |
Why?
|
| Carboxypeptidase B | 1 | 2004 | 2 | 0.010 |
Why?
|
| Carboxypeptidases | 1 | 2004 | 12 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 134 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2009 | 568 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 178 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 99 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 350 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2004 | 181 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 318 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 130 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 196 | 0.010 |
Why?
|
| Thermodynamics | 1 | 2006 | 380 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 396 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2003 | 60 | 0.010 |
Why?
|
| Cysteine | 1 | 2004 | 171 | 0.010 |
Why?
|
| Glyoxylates | 1 | 2003 | 9 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 10446 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 507 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 161 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2005 | 198 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 353 | 0.010 |
Why?
|
| Renal Blood Flow, Effective | 1 | 2003 | 2 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 250 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2003 | 44 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 637 | 0.010 |
Why?
|
| Instillation, Drug | 1 | 2002 | 9 | 0.010 |
Why?
|
| Monokines | 1 | 2002 | 24 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2002 | 41 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 283 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 380 | 0.010 |
Why?
|
| Metaplasia | 1 | 2002 | 54 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 407 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2002 | 132 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 380 | 0.010 |
Why?
|
| Carbon Monoxide | 1 | 2002 | 64 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 762 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 248 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2004 | 210 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 2002 | 16 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 677 | 0.010 |
Why?
|
| Neurons | 1 | 2010 | 1277 | 0.010 |
Why?
|
| Insulinoma | 1 | 2002 | 29 | 0.010 |
Why?
|
| Cell Count | 1 | 2002 | 303 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 365 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1003 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2002 | 150 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1204 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 188 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 247 | 0.010 |
Why?
|
| Motor Activity | 1 | 2006 | 635 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 918 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2002 | 135 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2002 | 312 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2003 | 315 | 0.010 |
Why?
|
| Trachea | 1 | 2002 | 223 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 665 | 0.010 |
Why?
|
| Fibrosis | 1 | 2003 | 452 | 0.010 |
Why?
|
| Nicotine | 1 | 2002 | 265 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2002 | 552 | 0.010 |
Why?
|
| Echocardiography | 1 | 2003 | 569 | 0.010 |
Why?
|
| Ischemia | 1 | 2003 | 361 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 605 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 847 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 1638 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 615 | 0.010 |
Why?
|